Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Mayo Clinic
- Study ID
- NCT06315595
- Status
- Recruiting
Conditions
- Prostate Neoplasm
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Non-Interventional Study — OTHERNon-interventional study
Study Details
This study evaluates if technical improvements in MRI can be used to provide improved performance contrast-enhanced MRI as used for angiography and perfusion as well as in non-contrast MRI.
Key Dates
- Start date
- Sep 30, 2015
- Status verified
- Apr 2026
- Primary completion
- Sep 30, 2030
- Completion
- Sep 30, 2030
Study Design
- Enrollment
- 1,000 participants (estimated)
Arms
- Arm: ObservationalParticipants undergo a non-contrast MRI on study and may optionally undergo a second non-contrast MRI on study. Participants may also undergo blood sample collection on study.
Primary Outcome Measure
Improved performance in contrast-enhanced magnetic resonance imaging (MRI) as used for angiography and perfusion [ Time Frame: Baseline (at enrollment); possible second scan at a later date ]
Central Contacts
- Clinical Trials Referral Office855-776-0015
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | - |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Clinical Trials Referral Office 855-776-0015 Stephen J. Riederer, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Scottsdale, AZ
Related Studies
- Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate BrachytherapyPHASE1/PHASE2 · Recruiting · Washington University School of Medicine · St Louis, Missouri
- The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac StudyRecruiting · UMC Utrecht · Pittsburgh, Pennsylvania
- MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted BiopsyRecruiting · University of Chicago · Chicago, Illinois
- Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation TherapyPHASE2 · Recruiting · Shehzad Basaria, M.D. · Boston, Massachusetts